Correction to: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials (Nature Communications, (2023), 14, 1, (4347), 10.1038/s41467-023-40057-8)

Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A.F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. KellyTonya Villafana

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-023-40057-8, published online 19 July 2023 The original version of this Article contained an error in Fig. 3b, in which amino acid frequencies at positions 64, 68 and 208 for the ‘Phase 2b’ trial, and at position 204 for the ‘MELODY’ trial were incorrect. The correct version of Fig. 3 is: (Figure presented.) which replaces the previous incorrect version: (Figure presented.) This has been corrected in both the PDF and HTML versions of the Article.

Original languageEnglish
Article number3026
JournalNature Communications
Volume15
Issue number1
DOIs
StatePublished - 1 Dec 2024

ASJC Scopus subject areas

  • General Chemistry
  • General Biochemistry, Genetics and Molecular Biology
  • General Physics and Astronomy

Fingerprint

Dive into the research topics of 'Correction to: Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials (Nature Communications, (2023), 14, 1, (4347), 10.1038/s41467-023-40057-8)'. Together they form a unique fingerprint.

Cite this